The global prevalence of diabetes mellitus is escalating daily (Khan, 2024; Khan et al., 2025). In Pakistan, the high costs of therapy and diagnosis approximately 11,580 PKR annually and 965 PKR/month, with 46% of these costs attributed to medications and 32% to laboratory investigations consume about 18% of a family’s income (Nasiri et al., 2019). Coupled with the complications of diabetes mellitus and oxidative stress (Naz et al., 2024) and in-turn significant noncompliance rates (Khan, 2022), these factors necessitate recognizing pharmacists as key stewards in diabetes management.
Abstract
Share on Mobile
Scan to access on mobile
Keywords
Letter to Editor
Content
No content available